Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo Phase 3 ORCA-2 Trial to Enroll 750 Smokers Across 15 Clinical Trial Sites in the United States SEATTLE, Wash and VANCOUVER, British Columbia, October 7, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the promotion of John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve’s Chief Financial and Operating…
/Read More
Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020 SEATTLE, Wash and VANCOUVER, British Columbia, September 18, 2020 — Achieve…
/Read More
Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix SEATTLE, Wash and VANCOUVER, British Columbia, September 18, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation,…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, September 10, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that cytisinicline data will be featured in two presentations on Friday, September 18th, at the SRNT-E virtual conference. Both presentations evaluate…
/Read More